Integral Health Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Integral Health Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-387,000	Closed	-$4.86M	–	77
2023 Q2	$4.86M	Buy	387,000 +82,000	+27%	+$973K	0.6%	56
2023 Q1	$3.38M	Sell	305,000 -22,000	-7%	-$271K	0.68%	52
2022 Q4	$3.99M	Buy	327,000 +197,000	+152%	+$2.22M	0.84%	43
2022 Q3	$1.36M	Sell	130,000 -574,490	-82%	-$6.4M	0.26%	62
2022 Q2	$7.57M	Buy	704,490 +480,490	+215%	+$3.96M	1.56%	22
2022 Q1	$2.12M	Buy	224,000 +49,000	+28%	+$459K	0.55%	54
2021 Q4	$2.02M	Sell	175,000 -250,000	-59%	-$2.79M	0.56%	54
2021 Q3	$4.06M	Sell	425,000 -50,000	-11%	-$511K	1.17%	34
2021 Q2	$4.58M	Buy	+475,000	New	+$4.64M	1.26%	32

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Integral Health Asset Management's FOLD Position: Q3 2023 in Review

Integral Health Asset Management sold out of Amicus Therapeutics (FOLD) in Q3 2023, closing a stake of 387,000 shares — an estimated $4.86M sold.

Integral Health Asset Management first reported a position in FOLD in Q2 2021 and held it in 9 quarters. The position peaked at $7.57M in Q2 2022. 228 funds tracked by Wall St. Rank hold FOLD as of Q3 2023.

Integral Health Asset Management reported no remaining Amicus Therapeutics position as of Q3 2023 after selling out during the quarter.
Integral Health Asset Management sold 387,000 Amicus Therapeutics shares in Q3 2023, an estimated $4.86M.
Integral Health Asset Management first reported a position in Amicus Therapeutics in Q2 2021 and held it in 9 quarters.
Integral Health Asset Management's Amicus Therapeutics position peaked at $7.57M in Q2 2022.
228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2023.

Based on Integral Health Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.